Dural Arteriovenous Malformations: A Review of the Literature and a Presentation of the JHN Series

Ed Marchan
Stavropoula Tjoumakaris
Robert H. Rosenwasser MD
Thomas Jefferson University
L. Fernando Gonzalez
Ciro Randazzo MD
Thomas Jefferson University

See next page for additional authors

Follow this and additional works at: https://jdc.jefferson.edu/jhnj
Let us know how access to this document benefits you

Recommended Citation
Marchan, Ed; Tjoumakaris, Stavropoula; Rosenwasser MD, Robert H.; Gonzalez, L. Fernando; Randazzo MD, Ciro; and Jabbour, Pascal MD (2010) "Dural Arteriovenous Malformations: A Review of the Literature and a Presentation of the JHN Series," JHN Journal: Vol. 5 : Iss. 2 , Article 2.
DOI: https://doi.org/10.29046/JHNJ.005.2.002
Available at: https://jdc.jefferson.edu/jhnj/vol5/iss2/2

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in JHN Journal by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
Dural Arteriovenous Malformations: A Review of the Literature and a Presentation of the JHN Series

Authors
Ed Marchan, Stavropoula Tjoumakaris, Robert H. Rosenwasser MD, L. Fernando Gonzalez, Ciro Randazzo MD, and Pascal Jabbour MD

This review article is available in JHN Journal: https://jdc.jefferson.edu/jhnj/vol5/iss2/2
Dural Arteriovenous Malformations: A Review of the Literature and a Presentation of the JHN Series

Edward M. Marchan, MD, Stavropoula I. Tjoumakaris, MD, Robert H. Rosenwasser, MD, L Fernando Gonzalez, MD, Ciro Randazzo, MD, MPH, Pascal M. Jabour, MD

Department of Neurological Surgery, Thomas Jefferson University, Philadelphia, PA

Risk Stratification and Management Strategies

Introduction

Epidemiology
Dural arteriovenous malformations (DAVMs), also known as dural arteriovenous fistulas, are arteriovenous shunts from a dural arterial supply to a dural venous channel, typically supplied by pachymeningeal arteries and located near a major venous sinus. The etiology of these lesions is not fully understood. DAVMs in the pediatric population are associated with structural venous abnormalities, but the majority of DAVMs are thought to be acquired. Different etiologies have been implicated in this phenomenon, namely: sinus thrombosis, trauma or surgery.

DAVMs have been reported in all age groups, but mainly in the fifth and sixth decades of life. The estimated incidence of DAVMs is 0.17 per 100,000 and they are one fifth as common as arteriovenous malformations (AVMs). They represent 10% to 15% of all intracranial vascular malformations, with a higher incidence in women. In fact, a female/male ratio of 2/1 exists in certain anatomic sites such as the cavernous and transverse-sigmoid sinuses. AVMs are usually solitary, nonetheless in 5% of cases multiple lesions have been described.

Natural History
DAVMs are usually acquired. Recent experimental work suggests that the wide array of clinical associations of DAVMs may be explained by the development of venous obstruction and hypertension with aberrant angiogenesis. It is hypothesized that their development arises from altered angiogenesis within the dura following an inciting event such as trauma, surgery or chronic infection. Sinus thromboses can be an accompanying factor in these cases. Cases have been documented of angiographically proven dural sinus thrombosis in which DAVMs subsequently developed as a consequence of the obstructed sinus. Next, initial microshunts proliferate in association with venous hypertension, and mature into clinically significant arteriovenous fistulae. The degree of progression or involution determines the significance of the abnormality. These fistulae may result in hemorrhage or other focal manifestations including hemodynamic insufficiency. DAVMs cause decreased regional cerebral blood flow in cortical regions where there is retrograde venous drainage.

The development of DAVMs following trauma and surgery is well known. They have also been reported in association with chronic infection, vascular disease and tumors. DAVM have no clear association. They may be identified at anatomical sites distant from the presumed inciting event. The exact mechanism of development remains unclear. It is well established that the development of a DAVM in these diverse settings requires a common mechanism as well as a possible anatomic or genetic predisposition.

An established DAVM may follow one of several unpredictable natural courses. Some lesions remain asymptomatic or maintain stable clinical symptomatology and angiographic features over many years. Others undergo spontaneous regression, involution and resolution with stabilization or improvement of neurological symptoms. Features that may predispose to such spontaneous involution are not known. In fact, DAVMs in the region of the cavernous sinus are particularly prone to this phenomenon with as many as 40 percent of reported cases having undergone spontaneous involution.

In contrast, some DAVMs may demonstrate increase in size from either arterial or venous enlargement or even de novo development. Pachymeningeal arterial feeders may be progressively recruited with enlargement of the nidus. The mechanisms behind this progressive recruitment of arterial feeders from numerous sources have not been elucidated. This phenomenon results in hypertrophy of dural arteries and the reappearance of involuted embryonic arteries that may not normally be visible in the adult dura mater. In some DAVMs there is also progression of pathology on the venous side. Progressive arterIALIZATION of the pathologic dural leaflets results in hypertension in adjacent leptomeningeal venous channels. This may lead to retrograde leptomeningeal venous drainage. Under arterialized pressures these channels may become tortuous and, eventually, varicose or aneurysmal. The catastrophic consequence that ensues is a cerebral hemorrhage from cortical venous drainage. In DAVMs that present with intracranial hemorrhage and have retrograde cortical venous drainage, there is a 35% risk of rebleeding within the first 2 weeks.

Presentation
Clinical manifestations of DAVMs are highly variable and are related primarily to the location of the fistula as well as from the retrograde cortical venous drainage as described above. These range from minor symptoms to intracranial hemorrhage. The vast majority of symptoms can be attributed to the primary or secondary venous manifestations of the DAVM. Presentation may be sudden or slowly progressive. The degree and type of symptoms are determined by venous topography, venous flow pattern and the capacity of surrounding compensatory venous drainage. As above, the most serious neurological sequelae from DAVMs are associated with retrograde leptomeningeal venous drainage. Focal neurological deficits likely result from venous hypertension and intracranial hemorrhage from rupture of arterialized leptomeningeal veins.
Table I: Classification of DAVMs

<table>
<thead>
<tr>
<th>Type</th>
<th>Djindjian</th>
<th>Cognard</th>
<th>Borden</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Normal antegrade flow into dural sinus</td>
<td>Normal antegrade flow into dural sinus</td>
<td>Drains directly into venous sinus or meningeal vein</td>
</tr>
<tr>
<td>II</td>
<td>Drainage into venous sinus with reflux into adjacent sinus or cortical vein</td>
<td>a. Retrograde flow into sinus</td>
<td>Drains into dural sinuses or pachymeningeal veins with retrograde drainage into subarachnoid veins.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>b. Retrograde filling of cortical veins only</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>c. Retrograde drainage into sinus and cortical veins</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>d. Drains into dural sinus or meningeal veins with retrograde drainage into subarachnoid veins.</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>Drainage into cortical veins with retrograde flow</td>
<td>Direct drainage into cortical veins with retrograde flow</td>
<td>Drains into subarachnoid veins without dural sinus or meningeal involvement</td>
</tr>
<tr>
<td>IV</td>
<td>Drainage into venous pouch (lake)</td>
<td>Direct drainage into cortical veins with venous ectasia &gt;5mm and 3x larger than diameter of draining vein</td>
<td></td>
</tr>
<tr>
<td>V</td>
<td></td>
<td>Drainage to spinal perimedullary veins</td>
<td></td>
</tr>
</tbody>
</table>

There are a wide variety of non-hemorrhagic symptoms.40-42 More benign symptoms of pain, tinnitus or bruit are related to arteriovenous shunting and flow in the DAVM. Pulsatile tinnitus or other subjective auditory symptoms may occur with or without pain. These symptoms are likely to be related to high flow through dural venous channels at the base of the skull. Other painful complaints may be related to orbital congestion or stretching of dural leaflets by engorged vascular channels, or to direct compression of the trigeminal nerve by arterialized venous structures near the petrous apex. A variety of neuro-ophthalmologic manifestations of DAVMs include visual and gage abnormalities caused by venous hypertension, as well as orbital or ocular venous hypertension with resulting orbital crowding, venous stasis retinopathy and glaucoma. Other cranial DAVMs may present with symptoms of increased intracranial pressure (ICP) or a poorly defined headache.41-42 While the headaches are non-specific, there does appear to be an association with the dysplastic changes in meningeal vessels which are often present in DAVMs. There are also a wide spectrum of presenting focal neurological symptoms including seizure, hearing loss, cranial nerve palsy, papilledema and other visual symptoms and focal motor/sensory deficits.43-47

DAVMs may also result in altered cerebrospinal (CSF) hydrodynamics.48 Dilated venous structures may act as mass lesions, obstructing the CSF circulation and causing hydrocephalus. In other cases, dural venous hypertension may result in decreased absorption of CSF with secondary intracranial hypertension and papilledema. This latter complication appears to be more common in association with high flow lesions draining into large dural venous sinuses and in the setting of concomitant dural sinus outflow obstruction.

Particular clinical presentations take place with DAVMs in specific locations.12,38,39,40 DAVMs in the region of the transverse or sigmoid sinus, or near the cavernous sinus, often drain into the associated venous sinuses and may cause a variety of clinical manifestations due to flow or local venous engorgement. A high flow in the region of the transverse-sigmoid sinus junction, for example, often results in pulsatile tinnitus, headache and bruit. This phenomenon does not lead to bleeding or cause other deficits unless there is associated retrograde leptomeningeal venous drainage. Lesions at the anterior cranial fossa or the tentorial incisura rarely drain into a patent dural venous sinus and are more frequently associated with leptomeningeal venous drainage. They are more likely to cause serious clinical sequelae from venous hypertension and hemorrhage. It is important to mention that hemorrhage has not been reported in the absence of this feature; in all published cases with carefully documented diagnostic studies, hemorrhage from DAVMs is associated with rupture of arterialized venous structures. The prognosis of a first hemorrhage from DAVMs is ominous, and is associated with a greater than 30 percent mortality or serious disability. Hemorrhage from DAVMs in anticoagulated patients has uniformly been fatal.

Classification

Location
Classification of DAVMs has evolved over time to be useful in guiding therapeutic intervention. Initial attempts were simplistic, emphasizing the anatomic location (e.g., transverse-sigmoid DAVM, cavernous DAVM, sagittal sinus DAVM, convexity DAVM, tentorial and posterior fossa DAVM). These lacked meaningful information in regard to predicting the nature or outcome of the abnormality or treatment options. Subsequent systems incorporated information from diagnostic angiography.49-50

Venous drainage
Perhaps one of the most well recognized classification schemes specific to DAVMs is that developed by Djindjian et al.49 This system categorizes a lesion into one of four types: type I DAVMs are characterized by normal antegrade drainage into a venous sinus or meningeal vein; type II lesions drain into a sinus, with reflux into adjacent sinuses or cortical veins; type III DAVMs drain directly into cortical veins with resultant retrograde flow into the cerebral venous compartment; type IV DAVMs have drainage directly into a venous pouch (venous lake or venous ectasia). They concluded from their study that type I DAVMs were benign, with each sequential type having more aggressive characteristics. Since the introduction of the Djindjian classification of DAVMs, other studies have been published in the literature attempting to correlate certain features of the DAVM with the likelihood of associated hemorrhage or other specific neurologic complications.40,51,52
With the advent of more effective endovascular therapeutic techniques, a means of predicting lesion risk and management options emerged. Cognard et al. developed a classification system derived from a modified version of that published by Djindjian et al. Cognard defined five types of DAVMs that are exclusively based on the pattern of venous outflow. As such, type I DAVMs were characterized by normal antegrade flow into the affected dural sinus. Type II lesions were associated with an abnormal direction of venous drainage within the affected dural sinus. These lesions could be further categorized into three subtypes: type IIa, lesions with retrograde flow exclusively into the sinus or sinuses; type IIb, lesions with retrograde venous drainage into the cortical veins only; and type IIa+b, lesions with retrograde drainage into sinuses and cortical veins. Type III DAVMs drained directly into a cortical vein or veins without venous ectasia, whereas type IV DAVMs had drainage into cortical veins with the critical component of venous ectasia greater than 5 mm in diameter and three times larger than the diameter of the draining vein. A DAVM was considered to be type V when drainage was into spinal perimedullary veins. Correlation with their clinical data yielded the following conclusions: Type I DAVMs are considered benign, and treatment is usually not necessary, except possibly for palliation of symptoms; type IIa lesions are best treated with arterial embolization; while type IIb and IIa+b lesions usually require both transarterial and transvenous embolization for effective obliteration. For those lesions of types III through V, transarterial and occasionally transvenous embolization aimed at complete occlusion of the fistula is necessary and usually will need to be combined with surgical techniques in eradicating the threatening cortical venous drainage.

Meanwhile, Borden, et al., also proposed a classification system emphasizing venous anatomy. This system is appealing in its simplicity, with only 3 categories. Type I dural AVMs drain directly into dural venous sinuses or pachymeningeal veins. Type II malformations drain into dural sinuses or pachymeningeal veins but also have retrograde drainage into subarachnoid (leptomeningeal) veins. Type III malformations drain solely into subarachnoid (leptomeningeal) veins and do not have dural sinus or meningeal venous drainage. The validity of both the Cognard and Borden classification systems were confirmed in 102 intracranial DAVMs in 98 patients. (Table I)

Risk stratification
Regardless of lesion location or previous clinical presentation or other symptomatology, the most important factor determining the propensity of a lesion to an aggressive clinical course appears to be the presence of leptomeningeal venous drainage. Lesions that drain into a large patent venous sinus may have various clinical associations but do not bleed or cause focal neurological deficits unless associated with retrograde leptomeningeal venous drainage. Lesions without drainage into a patent dural venous sinus more frequently are associated with leptomeningeal venous drainage and more often are prone to more serious clinical sequelae, such as an intracerebral hemorrhage. As discussed, the risk of hemorrhage appears to be related directly to the presence of tortuous and aneurysmal leptomeningeal arterialized veins in association with DAVMs.

Treatment
General principles of treatment
A DAVM may rarely be discovered on routine imaging studies on digital subtraction angiography performed for other indications. Incidental lesions must be carefully assessed for features predisposing to aggressive clinical behavior. Complete angiographic evaluation is indicated in every case of suspected DAVM unless the patient is a poor candidate for therapeutic intervention or refuses invasive diagnostic studies. Lesions should be evaluated specifically for the presence of leptomeningeal venous drainage and for any variceal, aneurysmal changes in the venous circulation or venous ectasia. In the absence of these features, the lesion should be followed expectantly. There is no evidence to justify prophylactic treatment of DAVMs that are not associated with leptomeningeal cortical venous drainage. Expectant follow-up of these lesions should include serial MR imaging for any evidence of development of leptomeningeal venous dilations. Angiographic re-examination of the lesion every few years should be considered, especially for DAVMs at the anterior cranial fossa or the tentorial incisura, which as discussed, very commonly harbor leptomeningeal venous drainage.

Definitive prophylactic treatment should be strongly considered for asymptomatic and incidentally discovered DAVMs with leptomeningeal venous drainage. The patient should be given the option of open surgical intervention or such alternative radiosurgical or endovascular options as may be appropriate for the specific lesion type and location. If treatment does not succeed at totally eliminating leptomeningeal venous drainage, either further definitive therapy or very close follow-up of the lesion is indicated. It is our belief that anticoagulation is contraindicated in the setting of DAVMs with leptomeningeal venous drainage.

Definitive intervention for DAVMs that in the past behaved aggressively warrants more serious thought. Nevertheless, the morbidity of a first hemorrhage with DAVMs is substantial, and many patients do not survive or do not recover to a condition suitable for therapeutic intervention. Furthermore, little is known about the risk either of subsequent hemorrhage or of the progression of neurological deficits in this clinical setting. However, there are numerous documented cases of progression of focal neurological symptoms resulting in death or major disability unless the DAVM is obliterated. It is our recommendation that lesions that have hemorrhaged or that cause focal neurological symptoms due to parenchymal venous hypertension be considered for definitive treatment. Palliative therapy is not sufficient in this setting.

On the other hand, lesions that present with pain or pulsatile tinnitus are evaluated and treated in the same way as incidental lesions. Nonspecific measures aimed at the symptoms are usually sufficient. Palliative treatment of the DAVM may be considered for the control of symptomatology. Rarely is definitive treatment indicated solely for pain or pulsatile tinnitus. We do not believe that the risk of definitive treatment is justified in such DAVMs as they do not exhibit leptomeningeal venous drainage.

Lesions associated with ophthalmoplegia are evaluated on a case-by-case basis. Frequently, painful ophthalmoplegia will resolve spontaneously, and many such lesions involute after angiography. In other cases, ophthalmoplegia may be progressive or associated with retinopathy and visual loss. In such situations, treatment of the associated DAVM is justified. Palliative treatment may be sufficient to stabilize visual symptoms. Again, a radical cure of the DAVM should not be pursued at any risk, and is generally not warranted unless the symptoms are truly debilitating or the DAVM is associated with leptomeningeal venous drainage.

The management of DAVMs associated with papilledema and increased intracranial pressure has been discussed previously. Palliation or definitive cure of the DAVM frequently (but not always) results in reversal of papilledema and stabilization of visual symptoms. Again, in the absence of leptomeningeal venous drainage, the risk of radical lesion treatment...
Figure 1
This is a 46 yo female who underwent embolization of a Right Temporo-Occipital DAVM. A) and B) Pre-embolization digital subtraction angiography (DSA) images showing multiple arterial feeders (mostly from the occipital-meningeal system). C) and D) Post-embolization DSA showing no supply from the meningeal system or occipital system after only one embolization session.

may not be justified, and may or may not result in subsequent control of intracranial hypertension. Cerebrospinal fluid diversion via lumboperitoneal shunting or optic nerve sheath decompression may be combined with transarterial embolization and or radiosurgery in the management of these entities. Transvenous occlusion is rarely possible in this setting, as it may further compromise intracranial venous outflow. Lumboperitoneal shunting or optic nerve sheath decompression may effectively treat
the secondary complications of papilledema while the DAVM is followed expectantly, treated palliatively, or with radiosurgery. Ventriculoperitoneal shunting may not be possible in view of small cerebral ventricles, and may be dangerous in the setting of arterialized cortical or subependymal veins.

In summary, clinical symptoms other than hemorrhage and progressive neurological deficits rarely warrant radical treatment of a DAVM, unless the lesion is particularly accessible.
or is associated with features predisposing to subsequent aggressive clinical behavior. Patient reassurance, symptomatic treatment, or lesion palliation is frequently sufficient. In DAVMs with features predisposing to an aggressive clinical course, a more definitive treatment strategy should be adopted. It is obvious that the myriad of clinical manifestations of DAVMs and the wide spectrum of possible angiographic and pathophysiologic scenarios call for highly individualized management strategies. Diagnostic investigation should be thorough so as to identify DAVMs with features predisposing to aggressive clinical behavior such as leptomeningeal cortical venous drainage or venous ectasia. Treatment strategies should include a highly individualized choice of modalities from the available armamentarium of symptomatic treatment, lesion palliation, transarterial and/or transvenous endovascular therapy, open surgical invention, and radiosurgery. For the foreseeable future, the treatment of DAVMs should preferably be entrusted to multidisciplinary teams with expertise in the recognition and management of these lesions, and with experience in a variety of treatment options approaches.

Treatment strategy and location

Surgery

The goals of surgical treatment of DAVMs include 1) physical interruption or obliteration of arterialized leptomeningeal venous connections and 2) maximal coagulation or excision of the pathological dura. There is a continuous risk for significant blood loss. This is particularly true early in the procedure when incomplete exposure may be accompanied by significant bleeding. From the early steps of skin infiltration and incision, the operation should proceed in small steps, with hemostatic control before the subsequent step. This approach is indeed more speedy, efficient and safe than having to take time to control brisk bleeding from many sources. As a rule, no incision should be made unless one was prepared to control catastrophic bleeding from it. A thorough review of preoperative angiography and judicious use of preoperative embolization helps to limit this risk. Continuous communication with the anesthesia team is critical.

Meticulous attention to hemostasis and microsurgical technique is imperative throughout the procedure. Following identification, resection of the abnormal dura is aided by the irrigating bipolar. Small permanent vascular clips in tandem, alternated with dural transection may be useful. Temporary aneurysm clips are helpful in decision making prior to coagulation and sectioning of variceal veins, which may significantly impact adjacent cortical venous circulation. It is sometimes possible to identify discrete arteriovenous connections whose occlusion significantly decreases surrounding subarachnoid venous engorgement. Direct puncture of large varices with intraoperative placement of obliterating coils has been used successfully. A combination of coils and glue after obtaining access by craniectomy and direct sinus puncture has also been reported. Resection of the dural sinus can be accomplished without the risk of venous infarction if the resected segment is arterialized and collateral channels are well developed. In some cases, surgical clipping of the draining vein close to the DAVM, with extensive dural coagulation rather than resection may be preferred. Recently, presigmoid skull base exposures have been employed, specifically for access to petrolal and sigmoid lesions. Image guided frameless navigation is useful for flap design and localization of DAVMs or associated cortical venous drainage. Intraoperative angiography helps to ensure complete resection in difficult cases.

Endovascular techniques

Transarterial embolization has been widely used in the treatment of DAVMs. The use of flow-guided catheter technology and increased experience with particle and glue embolization as well as detachable coils have greatly improved the safety and efficacy of this method. Transarterial embolization rarely succeeds in totally eliminating and curing a DAVM, except in rare instances of limited fistulae with a small number of accessible feeders. More commonly, DAVMs involve a multitude of feeders, which often arise as small twigs from major cerebral arteries that are not amenable to embolization. While transarterial embolization may obliterare the filling of the lesion after one injection, the DAVM often continues to draw feeders from other sources, and will reappear on subsequent angiography, possibly in a more ominous configuration. DAVMs that are partially treated with transarterial embolization may later recur and progress to catastrophic hemorrhage.

What transarterial embolization can do is to palliate disabling symptoms even when it does not totally cure the DAVM. Symptom palliation may be accomplished by transarterial embolization of external carotid artery feeders to the DAVM, although such an intervention is not without risk and rarely succeeds in totally eliminating the DAVM. Arterial embolization may give a false sense of security that the lesion was “treated” while the DAVM may progress to acquire more aggressive features including leptomeningeal venous drainage (even in the absence of recurrent symptoms). DAVMs that are followed expectantly or treated palliatively should be monitored closely with serial diagnostic studies to watch for the development of leptomeningeal venous drainage, which may occur without change in clinical symptoms. Such lesions should continue to be followed as discussed above. Transarterial embolization also plays an important role in decreasing flow through DAVMs prior to surgical intervention, transvenous obliteration, or radiosurgery. This adjunctive, preparatory use of transarterial embolization has greatly enhanced the safety and efficacy of other more definitive treatment measures.

Noninvasive imaging methods, including MRI and MRA may be used for interval studies, although these modalities may miss subtle development of leptomeningeal venous drainage, which may be clinically catastrophic. Depending on the clinical situation and the particular lesion, serial MR studies may be performed on a yearly basis, with formal angiography every few years or sooner if symptoms change, or if there is a suggestion of new leptomeningeal venous drainage on MRI. Transvenous endovascular obliteration of DAVMs has recently been used with good results. This modality aims at the thrombosis of the venous side of the lesion, often including the obliteration of the adjacent dural venous sinus. Occlusion of the venous side of DAVMs is usually well tolerated if the pathologic dural sinus is arterialized and does not serve as a site of drainage of cerebrovenous circulation. Instead, the pathologic dural segment is often associated with harmful retrograde leptomeningeal venous drainage, and these channels are secondarily obliterated with thrombosis of the venous side of DAVMs. This strategy has been used most successfully for the treatment of DAVMs with accessible venous drainage. Transvenous obliteration is particularly effective in the treatment of cavernous sinus DAVMs (access through the inferior petrosal sinus), although these lesions frequently do not require any therapeutic intervention because of their benign clinical symptomatology and tendency toward spontaneous regression.
Transvenous obliteration has also been used in cases of transverse-sigmoid sinus DAVMs, and may be substantially safer than open surgical approaches to these lesions. However, there may be no accessible transvenous route for many DAVMs, including tentorial incisura DAVMs and anterior cranial fossa DAVMs, which frequently behave aggressively. Transvenous obliteration may occasionally be performed after open surgical exposure, through puncture of the dural venous sinus or the arterialized venous varix and the injection of coils or glue.66 Rarely, transvenous occlusion may result in propagating venous thrombosis or altered hemodynamic patterns with paradoxical clinical deterioration or hemorrhage.

Occasionally, a DAVM will recur adjacent to endovascularly occluded venous sinus, and this could represent reconstitution of arteriovenous channels within the walls of the occluded sinus, or in the organized thrombus within the sinus channel. These cases are amenable to surgical excision of the segment of occluded sinus, and disconnection of associated arterialized leptomeningeal veins.

Radiosurgery
The goal of radiosurgical treatment is sclerosis and obliteration of arteriovenous connections within the pathological dura, resulting in secondary thrombosis of the DAVM. Advantages include non-invasive treatment and avoidance of risks associated with invasive procedures. Disadvantages include delayed response to treatment and risk of radiation injury to normal structures in the vicinity of the DAVM. When combined with transarterial embolization, 95% of patients demonstrated symptomatic improvement and 87% demonstrated angiographic cure on angiography performed a median of 12 months following radiosurgery.79 There was an acceptable complication rate with this treatment strategy. Radiosurgery alone was effective when the DAVM was not amenable to embolization but the time course for symptomatic improvement was longer.

DAVMs of the transverse-sigmoid sinuses treated with a similar strategy yielded a 96% symptom resolution or significant improvement and a total or near-total obliteration at mean angiography 21 months following radiosurgery.66 There were no intracerebral hemorrhages or radiation-related complications. While the ideal treatment parameters and ultimate role of radiosurgery continue to evolve, it has an established role in the multi-modality treatment of DAVMs.

The Thomas Jefferson Experience
Background
We have amassed the longest reported follow-up of 39 patients who were initially treated by endovascular means. These patients were subsequently evaluated throughout their treatment plan in order to discern whether multi-modality therapy would be necessary or not or whether strict endovascular therapy would suffice. We hereby report their outcomes and complications. Our follow-up involves patients who were electively referred to our institution who had a non-invasive study (such as an MRA) illustrating the DAVM as well as those who presented with an intracerebral hemorrhage. The sequence of events involved a diagnostic angiogram followed by endovascular embolization as the primary means of treatment.

Thirty-nine patients (22 males and 17 females) underwent endovascular treatment of dural AVMs at our primary institution from 2001–2009. Ages ranged from 39–71 (mean age: 48). Seventy-nine percent of patients had cortical venous drainage.

Methods
We studied the following outcome factors: 1) the number of embolizations needed to obliterate the lesion, and 2) the percentage of patients requiring transvenous embolization, craniotomy, or radiosurgery for eradication of the lesion after endovascular management.

We also inspected whether those patients who were initially found to have retrograde cortical venous drainage had subsequent eradication of this phenomenon after multi-modality therapy. Finally, we assessed post operative complications from either of the modalities.

Results
Outcomes toward Obliteration of Fistulous Component
The number of endovascular embolizations performed in order to decide on whether to proceed with surgery, radiosurgery or ascertain complete obliteration of the fistula was 2.1. This was an average obtained by adding up the number of endovascular embolizations needed to obtain at least a 95% reduction in fistula flow in all patients studied. We deemed the DAVM as "treated" when this result was obtained as per the observation of the angiographer. Seventy-one percent (71%) (28/39) of patients had complete obliteration of the fistula; 21 of those by endovascular means and 7 via craniotomy. Figure 1 illustrates eradication of the DAVM after one embolization session.

Of the eleven patients who did not have complete obliteration of the fistula, seven of those (64%) had at least 90% obliteration with only one feeding pedicle remaining. Three patients needed radiosurgery as a final approach for treatment. The average dose utilized for eradication of the DAVM was 22 Gy in single fraction.

Outcomes Toward Eradication of Retrograde Cortical Venous Drainage
We studied whether retrograde cortical venous drainage would be eradicated by various components of multi-modality therapy. 87% (26/30) of patients had full obliteration of their cortical venous drainage. Of these 26 patients, 69% (18/26) had obliteration obtained by endovascular means while the rest needed surgical venous ligation. Figure 2 illustrates treatment of a patient by multi-modality therapy to eradicate both the cortical venous drainage phenomenon as well as the fistulous component. It is interesting to note that in five of these 18 patients who had CVD treated endovascularly, success was only obtained when a transvenous approach was performed.

Complications
The following complications were noticed: epidural infection after craniotomy (1), post op intracranial hemorrhage not requiring surgery after embolization (1), and need for vein patch procedure after uncontrolled femoral bleeding (1). All above complications were diagnosed and treated expeditiously.

Analysis
Endovascular treatment of DAVMs is a safe and effective way to treat these complex lesions. Additional modalities such as surgery and radiosurgery have become adjuvant in the treatment of these lesions. We strongly believe based on this data that endovascular embolization should be the primary modality for treating DAVMs.

Prognosis and outcome
An established DAVM has an unpredictable natural course, varying from spontaneous regression to more venous recruitment and hemorrhage, depending on the presence or absence of leptomeningeal venous drainage. The prognosis of a first hemorrhage from DAVMs is ominous, and has been shown to be associated with greater than 30% mortality or serious disability. The annual bleeding risk of a DAVM varies between 1.8 to 15%,71 the risk of rebleed over the period of two weeks has been estimated to be around 35%.72 The acute or gradual progression from one grade to the next has been described.
Any change in the bruit or symptoms of a DAVM should warrant reevaluation to rule out the development of alternative drainage paths such as leptomeningeal drainage pathways. Recently carotid duplex sonography has been reported as a tool for follow up of treated dural AVMs, with a correlation of the resistance index of the external carotid artery with the effectiveness of treatment.22

Conclusion
Much has been learned in recent years about the pathoanatomy, pathophysiology, natural history and therapeutic options for DAVMs. A better understanding of these lesions has allowed more prompt and precise diagnosis, and a realistic assessment of features predisposing to aggressive clinical course. Treatment is not only guided toward the palliation of clinical symptoms, but as importantly, toward prevention of future sequelae. The therapeutic armamentarium includes a number of options with varying risk and effectiveness for individual lesions. Transarterial embolization, transvenous embolization, surgical therapy or radiosurgery can be used alone or in various combinations as required for individual clinical scenarios.

References
March 2010

Announcing Jefferson’s Teleconsulting (JET) Robotic System for Help with Diagnosis and Treatment of Time-Sensitive Neurovascular Diseases

“Time is brain” is the credo among healthcare professionals for diagnosing and treating time-sensitive neurovascular diseases, including arteriovenous malformations (AVM), brain aneurysm and, especially, stroke. The need for immediate medical intervention is immense. For example, in the case of stroke, a patient having a stroke within 4.5 hours of symptom onset has the best chance of functional recovery. Timely performance of neurosurgical procedures to remove AVMs and aneurysms are similarly urgent. In many community hospitals, these services are not available or have limited experience and staff to diagnose and treat patients quickly and accurately.

Now, to provide sophisticated care and expertise to patients at hospital emergency rooms in small community hospitals in distant areas of southern Pennsylvania, south and central New Jersey, and Delaware, Jefferson Hospital for Neuroscience (JHN) in Philadelphia is launching Jefferson Expert Teleconsulting (JET), the region’s first university-based high-tech mobile robotic system for neurovascular care.

“JET places all of our resources — among them, dual-board-certified neurosurgeons, advanced technology, and leading-edge clinical trials, in which we partner with the National Institute of Health — at the disposal of patients, their families and physicians in need of second opinion,” says Robert H. Rosenwasser, MD, FACS, Professor and Chair, Department of Neurological Surgery, JHN.

“Stroke is the third-leading cause of death in the United States for the leading cause of disability. By a factor of this cost, every other disease,” Dr. Rosenwasser notes. “Given its prevalence and time-sensitive nature, it is alarming how few people receive treatment in the appropriate amount of time. With JET, expert hospitals in remote areas can provide patients with expert consultation and diagnosis of appropriate care from an experienced neurologist or neurosurgeon within minutes in cases where every minute can make a critical difference. It’s a very cost-effective approach to providing 24/7 on-site coverage and expertise.”

How JET works

Each participating hospital is equipped with a mobile robotic platform, manufactured by InTouch Health® of Santa Barbara, CA, that enables the JHN Network to remotely connect with a neurosurgeon, “the attending physician on call,” and transmit medical data to the remote physician.

“Should a patient arrive in the ED of a hospital located, say, three hours away from Jefferson and other hospitals have a neurologist or neurosurgeon available or have a local doctor who needs to consult with a neurosurgeon, Dr. Rosenwasser explains, “the attending physician can contact the JHN Network and select from one of our laptops to connect to the hospital’s ED. The JHN Network specialist on call then uses the laptop to connect to the remote hospital via the Internet, obtains a medical history by speaking directly with the patient and/or family members, examines the patient and determines what therapy is immediately needed, in real time, without delay. Finally, a decision is made either to admit the patient to the local hospital’s Critical Care Unit or transfer him or her to the Jefferson Acute Stroke Center by JET’s (Jefferson transport service, or the hospital’s own service.

“Patients may not need to be transferred — they can stay in their own community and be treated very successfully here, thanks to this program,” says Mr. Kolb. “And most patients want to stay close to home. JET stabilizes them to receive sophisticated medical care without having to travel long distances.”

“It also serves as an educational program,” adds Dr. Rosenwasser. “As a teaching center, JET will see JET to their clinical protocols with participating hospitals so that they can enhance stroke care within their communities. On the other hand, should the patient need an advanced neurosurgical procedure [for instance], we can arrange for prompt transfer.”

InTouch’s remote presence devices are the first and only with FDA approval. The robots allow direct contact to medical devices such as electronic stethoscopes, otoscopes and ultrasound to transmit medical data to the remote physician.

“The JET allows Jefferson physicians to remotely see and talk to the patient, and see and talk to the patient’s family members, and talk to the patient’s community hospitals to help advance stroke care throughout their community. On the other hand, should the patient need an advanced neurosurgical procedure [for instance], we can arrange for prompt transfer.”

InTouch (www.IntouchHealth.com) is the first and only FDA approved robotic telepresence technology.

JHN professional telepresence devices are equipped with video/stereo microscopes and high-performance cameras to transmit accurate and high-definition video and audio feeds. JET’s telepresence devices can be used in a variety of locations, including emergency departments, intensive care units and neurosurgical operating rooms. The remote presence devices allow Jefferson physicians to remotely see and talk to the patient, and see and talk to the patient’s family members, and talk to the patient’s community hospitals to help advance stroke care throughout their communities. On the other hand, should the patient need an advanced neurosurgical procedure [for instance], we can arrange for prompt transfer.”

InTouch’s remote presence devices are the first and only with FDA approval. The robots allow direct contact to medical devices such as electronic stethoscopes, otoscopes and ultrasound to transmit medical data to the remote physician.

“Patients may not need to be transferred — they can stay in their own community and be treated very successfully here, thanks to this program,” says Mr. Kolb. “And most patients want to stay close to home. JET stabilizes them to receive sophisticated medical care without having to travel long distances.”

“It also serves as an educational program,” adds Dr. Rosenwasser. “As a teaching center, JET will see JET to their clinical protocols with participating hospitals so that they can enhance stroke care within their communities. On the other hand, should the patient need an advanced neurosurgical procedure [for instance], we can arrange for prompt transfer.”